Journal of hepato-biliary-pancreatic sciences · 2016
Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoshizumi Tomoharu, Takada Yasutsugu, Shirabe Ken, Kaido Toshimi, Hidaka Masaaki, Honda Masaki, Ito Takashi, Shinoda Masahiro, Ohdan Hideki, Kawagishi Naoki, Sugawara Yasuhiko, Ogura Yasuhiro, Kasahara Mureo, Kubo Shoji, Taketomi Akinobu, Yamashita Natsumi, Uemoto Shinji, Yamaue Hiroki, Miyazaki Masaru, Takada Tadahiro, Maehara Yoshihiko
Аннотация
BACKGROUND: The natural history of human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) or HTLV-1 associated myelopathy, after liver transplantation is unclear.
METHODS: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors.
RESULTS: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5%, 6.5%, and 9.2%, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9%, 66.1%, and 66.1%, and from HTLV-1-positive donors were 83.3%, 83.3%, and 60.8%, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3%.
CONCLUSIONS: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.
METHODS: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors.
RESULTS: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5%, 6.5%, and 9.2%, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9%, 66.1%, and 66.1%, and from HTLV-1-positive donors were 83.3%, 83.3%, and 60.8%, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3%.
CONCLUSIONS: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.
Предметные рубрики MeSH
AdolescentAdultAgedCohort StudiesConfidence IntervalsFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHTLV-I InfectionsHospitals, UniversityHuman T-lymphotropic virus 1HumansIncidenceJapanLiver TransplantationLiving DonorsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPatient SelectionRetrospective StudiesRisk AssessmentSurvival AnalysisTransplant RecipientsYoung Adult